Alignment Investigation Overview
BFA is investigating whether Alignment Healthcare, Inc. committed securities fraud by misleading investors about Alignment’s operating expenses, capital expenditures, and adjusted EBITDA figures. Investors may be able to file a class action to potentially recover losses.
If you lost money on your Alignment investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Alignment being Investigated for Securities Fraud?
Alignment is being investigated for securities fraud following a significant stock drop. The decline in Alignment’s stock price caused significant losses to investors.
Alignment is a healthcare services company that operates a platform focused on managing Medicare Advantage plans.
BFA is investigating allegations that Alignment artificially inflated adjusted EBITDA to boost executive compensation.
Why did Alignment’s Stock Drop?
On July 8, 2026, reports emerged that Alignment’s former chief technology officer filed a whistleblower lawsuit alleging that Alignment purposefully misclassified $8 million to $10 million in routine operating expenses as capital expenditures to artificially inflate adjusted EBITDA and boost executive compensation. According to the lawsuit, these misclassifications enabled Alignment to report its first positive adjusted EBITDA of $1.3 million in 2024 instead of a loss between $7 million and $9 million.
Following that announcement, Alignment shares fell approximately 16.7% on July 8, 2026.
Alignment ($ALHC) Stock Chart
Image Caption: NASDAQ stock chart showing Alignment’s stock drop on July 8, 2026.
How Do I Submit My Information?
If you lost money when Alignment securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “Super Lawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
